Financialsexperimental
Absci Corp (ABSI). Every figure is as filed in the company's 10-Q and 10-K reports. Quarters a filing does not report on their own are worked out from its year-to-date figures and marked *.
USD in thousands · shares (whole numbers) · per-share amounts in USD
| Income Statement | Q2 FY26 30 Jun 2026 | Q1 FY26 31 Mar 2026 | Q4 FY25 31 Dec 2025 | Q3 FY25 30 Sept 2025 | Q2 FY25 30 Jun 2025 | Q1 FY25 31 Mar 2025 | Q4 FY24 31 Dec 2024 | Q3 FY24 30 Sept 2024 | Q2 FY24 30 Jun 2024 | Q1 FY24 31 Mar 2024 | Q4 FY23 31 Dec 2023 | Q3 FY23 30 Sept 2023 | Q2 FY23 30 Jun 2023 | Q1 FY23 31 Mar 2023 | Q4 FY22 31 Dec 2022 | Q3 FY22 30 Sept 2022 | Q2 FY22 30 Jun 2022 | Q1 FY22 31 Mar 2022 | Q4 FY21 31 Dec 2021 | Q3 FY21 30 Sept 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Partner program revenue | 318 | 215 | 650* | 378 | 593 | 1,179 | 665* | 1,701 | 1,270 | 898 | 338* | 744 | 3,367 | 1,269 | 1,435* | 2,004 | 636 | 454 | 1,087* | 1,390 |
| Collaboration revenue | 0* | 0 | 0 | 0 | 122* | 365 | 366 | 365 | 365* | 149 | ||||||||||
| Total revenues | 665* | 1,701 | 1,270 | 898 | 338* | 744 | 3,367 | 1,269 | 1,557* | 2,369 | 1,002 | 819 | 1,452* | 1,539 | ||||||
| Research and development | 22,616 | 19,275 | 25,347* | 19,249 | 20,458 | 16,364 | 18,377* | 17,985 | 15,261 | 12,236 | 12,269* | 11,029 | 12,112 | 12,657 | 11,315* | 15,525 | 16,241 | 15,827 | 15,766* | 10,730 |
| Selling, general and administrative | 9,164 | 9,058 | 8,617* | 8,441 | 8,528 | 9,472 | 8,828* | 9,256 | 9,346 | 8,744 | 9,324* | 9,505 | 9,410 | 9,593 | 7,749* | 11,407 | 10,507 | 10,889 | 9,183* | 9,733 |
| Depreciation and amortization | 2,696 | 2,728 | 2,828* | 2,842 | 3,000 | 3,072 | 3,234* | 3,355 | 3,384 | 3,416 | 3,484* | 3,513 | 3,498 | 3,504 | 3,586* | 3,404 | 3,141 | 2,906 | 2,759* | 2,218 |
| Total operating expenses | 34,476 | 31,061 | 31,691* | 30,532 | 31,986 | 28,908 | 30,439* | 30,596 | 27,991 | 24,396 | 25,077* | 24,047 | 46,355 | 25,754 | 22,650* | 30,336 | 29,889 | 29,622 | 27,708* | 22,681 |
| Operating loss | -34,158 | -30,846 | -31,041* | -30,154 | -31,393 | -27,729 | -29,774* | -28,895 | -26,721 | -23,498 | -24,739* | -23,303 | -42,988 | -24,485 | -21,093* | -27,967 | -28,887 | -28,803 | -26,256* | -21,142 |
| Goodwill impairment | 0* | 0 | 0 | 0* | 0 | 21,335 | ||||||||||||||
| Interest expense | -2 | -18 | -29* | -45 | -56 | -79 | -109* | -130 | -150 | |||||||||||
| Interest expense | -176 | -204* | -229 | -256 | -321 | -287* | -279 | -211 | -195 | -200* | -768 | |||||||||
| Other income, net | 990 | 1,283 | 1,346* | 1,597 | 1,011 | 1,458 | 921* | 1,664 | 2,121 | 1,711 | 1,446* | 1,572 | 1,583 | 1,458 | 1,409* | 675 | 148 | 125 | 188* | -3,427 |
| Total other income, net | 988 | 1,265 | 1,317* | 1,552 | 955 | 1,379 | 812* | 1,534 | 1,971 | 1,535 | 1,242* | 1,343 | 1,327 | 1,137 | 1,122* | 396 | -63 | -70 | -12* | -4,195 |
| Loss before income taxes | -33,170 | -29,581 | -29,724* | -28,602 | -30,438 | -26,350 | -28,962* | -27,361 | -24,750 | -21,963 | -23,497* | -21,960 | -41,661 | -23,348 | -19,971* | -27,571 | -28,950 | -28,873 | -26,268* | -25,337 |
| Income tax expense | -40 | -18 | 162* | -104 | -131 | 4 | -21* | -37 | -0 | -12 | -48* | -34 | -11 | -7 | 500* | 312 | 270 | -621 | 1,102* | 1,703 |
| Net loss | -33,210 | -29,599 | -29,562* | -28,706 | -30,569 | -26,346 | -28,983* | -27,398 | -24,750 | -21,975 | -23,545* | -21,994 | -41,672 | -23,355 | -19,471* | -27,259 | -28,680 | -29,494 | -25,166* | -23,634 |
| Net loss per share: basic (in usd per share) | -0.21 | -0.19 | -0.2 | -0.24 | -0.21 | -0.24 | -0.22 | -0.22 | -0.24 | -0.45 | -0.26 | -0.3 | -0.32 | -0.33 | -0.33 | |||||
| Net loss per share: diluted (in usd per share) | -0.21 | -0.19 | -0.2 | -0.24 | -0.21 | -0.24 | -0.22 | -0.22 | -0.24 | -0.45 | -0.26 | -0.3 | -0.32 | -0.33 | -0.33 | |||||
| Adjustment of redeemable preferred units and stock | 0* | 0 | ||||||||||||||||||
| Cumulative undeclared preferred stock dividends | 0* | 0 | 0 | 0 | 0* | 242 | ||||||||||||||
| Weighted-average common shares outstanding: basic (in shares) | 157,471,712 | 152,961,894 | 143,769,552 | 127,592,948 | 124,461,439 | 113,613,488 | 112,934,086 | 99,393,333 | 92,217,234 | 91,827,780 | 91,479,452 | 91,105,265 | 90,669,499 | 90,272,205 | 73,291,288 | |||||
| Net loss available to common stockholder basic | -19,471* | -27,259 | -28,680 | -29,494 | -25,166* | -23,876 | ||||||||||||||
| Weighted-average common shares outstanding: diluted (in shares) | 157,471,712 | 152,961,894 | 143,769,552 | 127,592,948 | 124,461,439 | 113,613,488 | 112,934,086 | 99,393,333 | 92,217,234 | 91,827,780 | 91,479,452 | 91,105,265 | 90,669,499 | 90,272,205 | 73,291,288 | |||||
| Net loss available to common stockholder diluted | -19,471* | -27,259 | -28,680 | -29,494 | -25,166* | -23,876 | ||||||||||||||
| Foreign currency translation adjustments | -52 | -65 | 33* | 14 | 324 | 77 | -183* | 161 | 43 | -47 | 18* | 78 | -42 | -14 | 11* | -27 | -40 | -10 | 2* | -4 |
| Unrealized loss on marketable securities | -102 | -222 | 58* | 175 | -32 | -54 | -72* | 204 | -25 | -48 | 4* | 9 | -9 | 39 | -157* | 114 | 2 | |||
| Comprehensive loss | -33,364 | -29,886 | -29,471* | -28,517 | -30,277 | -26,323 | -29,238* | -27,033 | -24,732 | -22,070 | -23,523* | -21,907 | -41,723 | -23,330 | -19,617* | -27,172 | -28,718 | -29,504 | -25,164* | -23,638 |